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Abstract. Aim: To examine the expression and function of
activin receptor-like kinase 7 (ALK7) in breast cancer, its
association with disease prognosis, and its impact on breast
cancer cell function. Patients and Methods: A cohort of patients
with breast cancer were examined for ALK7 expression in
association with pathological and clinical aspects. In vitro cell
assays of ALK7 were investigated using an expression plasmid.
Results: Overall higher levels of ALK7 transcripts were seen in
the breast cancer samples vs. normal tissue. However, within the
cancer cohort, lower levels of ALK7 transcript were associated
with poor prognosis. Patients with lower expression of ALK7
also had shorter survival. Overexpression of ALK7 reduced
proliferation and adhesion of breast cancer cells in vitro. We
found that overexpressed ALK7 had complex effects on the
MCF-7 cell sensitivity to chemotherapy drugs. Conclusion:
Decreased expression of ALK7 in breast cancer is correlated
with poor prognosis. ALK7 is a negative regulator of adhesion
and proliferation of breast cancer cells. This suggests that ALK7
is a potential tumor suppressor in breast cancer.
Breast cancer is currently the leading cause of cancer-
associated death for women, and is the most frequent female
malignancy worldwide. In the United States, breast cancer
alone is expected to account for 29% of all new cancer
diagnoses and 14% of total cancer deaths in women (1). This
represents an urgent public health problem, therefore, it is
vital to explore the molecular mechanisms underlying breast
cancer development and progression.
The transforming growth factor-β (TGF-β) superfamily
has been shown to regulate a variety of cellular processes
such as cell proliferation, differentiation, apoptosis, adhesion,
and migration, and play key roles in development and
carcinogenesis. The TGF-β superfamily encompasses more
than 35 members of structurally-related growth factors
including TGF-βs, activins, bone morphogenetic proteins
(BMPs), differentiation factors and other factors such as
nodal and its related proteins (1-3). TGF-β has been
implicated as playing paradoxical roles in breast
carcinogenesis, with both tumour-suppressing and pro-
oncogenic activities (4). The TGF-β superfamily transmits
their signals from the cell surface via transmembrane
serine/threonine kinase receptor complexes, consisting of
type I and type II receptors. In mammals, five type II
receptors and seven type I receptors (referred to as activin
receptor-like kinase, ALK 1-7) have been identified (3, 5-7).
Upon ligand binding, the type II receptors recruit and
transphosphorylate type I receptors. The latter, in turn,
phosphorylate the receptor-activated SMAD (small family
member, identified in Caenorhabditis elegans and mothers
against decapentaplegic homolog) proteins (R-SMADs).
Activated R-SMADs then form a protein complex with
SMAD4 and are translocated into the nucleus where they
interact with additional transcription factors and co-activators
or co-repressors to regulate target gene expression (1-3).
ALK7 was first discovered in the rat as an orphan
receptor (8) and was later reported to be able to mediate
signals of nodal, activin B, and activin AB (9, 10).
Functionally, activation of ALK7 has been shown to
suppress cell proliferation in the rat neuronal cell line PC12
(11). In addition, constitutively activated ALK7 induces
apoptosis of hepatoma and pancreatic β cells (12, 13).
Nodal acts via ALK7 to inhibit proliferation and induce
apoptosis of human trophoblast cells (14), and epithelial
ovarian cancer cells (15, 16). These findings support the
role of nodal–ALK7 pathway in mediating cell proliferation
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and apoptosis of cancer cells. Immunohistochemical
analysis has shown that ALK7 is more frequently and much
more intensely expressed in adjacent normal tissues,
adenosis, and fibroadenoma tissues than in malignant tissues
(17). In addition, the nodal–ALK7 signalling pathway has
been found to exert antiproliferative and proapoptotic
effects on breast cancer cells (18). 
In order to explore the role of ALK7 in breast cancer, the
present study aimed to examine the expression of ALK7 in
a cohort of human breast cancer samples and its association
with disease prognosis. We also investigated the impact of
this molecule on the function of breast cancer cells in vitro.
Materials and Methods
In silico analysis. Analysis of clinical data of breast cancer cases
was carried out using the manually curated Kmplot website
(http://kmplot.com/analysis/). All the gene-expression, relapse-free
and overall survival data were downloaded from GEO (Affymetrix
microarrays only), EGA and TCGA websites. A PostgreSQL server
was used to integrated gene expression and clinical data. The
median expression was used as the cut-off value which divided the
patients into two groups (high or low expression). The Kaplan–
Meier survival model was used to analyse the overall survival and
log-rank method to compare overall survival between two groups.
We utilsed two data sets for ALK7 expression in breast cancer, each
having 1660 patients. 
Cell lines and cell culture. Human breast cancer cell lines MDA-
MB-231, MCF-7, ZR-75-1, BT-20. BT-549, MDA-MB-436, BT-483
and SK-BR-3 were obtained from the European Collection of
Animal Cell Cultures (Salisbury, UK). Cells were routinely cultured
with Dulbecco’s modified Eagle’s medium (DMEM) containing
10% foetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml
streptomycin and 0.25 μg/ml amphotericin B at 37˚C with 5% CO2.
BT-483 cells were maintained in RPMI and SK-Br-3 were
maintained in McCoy’s 5A medium. 
For the hormone-starvation experiments, cells were cultured for
72 h in phenol red-free medium supplemented with 5% charcoal-
stripped foetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml
streptomycin and 0.25 μg/ml amphotericin B (starvation medium).
Cells were then treated with oestradiol (0-100 nM, final
concentration) and incubated for 24 h.
Human breast specimens. A total of 111 breast samples were
collected immediately after surgery and stored at −80˚C until use,
with approval of the BroTaf Health Authority local Ethics
Committee (Wales, U.K.) - approval numbers 01/4303 (19/12/2001)
and 01/4046 (06/08/2001). It included 91 breast cancer tissues and
20 normal breast tissues. A consultant pathologist verified all the
specimens used in the current study (Table I). 
RNA extraction and reverse transcription. Total RNA extraction from
frozen tissues and cultured cells was performed using Tri Reagent
(Sigma-Aldrich, Inc, St Louis’ MO, USA) following the manufacturer’s
protocols. RNA was quantified using a Nanodrop spectrophotometer.
RNA (0.5 μg) was reverse-transcribed using iScript™ cDNA Synthesis
Kit (Bio-Rad Laboratories, Hercules, CA, USA).
Polymerase chain reaction (PCR) for ALK7. PCR was then carried
out using a ReadyMix PCR Reaction Mix with MgCl2 (Sigma-
Aldrich, Inc.) on a 2720 Thermo Cycler (Applied Biosystems,
Warrington, UK). The sequences of ALK7 primer used were: Forward
(F): 5’-GACATGAAAACATCCTTGGT-3’, and reverse (R): 5’-
ACTTCTGGTCACAAACAACC-3’. Reactions were carried out
under the following conditions: 94˚C for 5 min, 30 cycles of 94˚C for
30 s, 55˚C for 30 s and 72˚C for 30 s, followed by a final extension
of 7 min at 72˚C. PCR products were separated on a 1.5% agarose
gel and photographed using a VisiDoc-It imaging system (Ultra-Violet
Products Ltd, Upland, CA, USA) after staining with SYBR safe dye. 
Real-time quantitative (q)PCR. Transcript levels were determined
using real-time PCR based on Amplifluor technology (19). An
additional sequence was added to one of the primers, known as the
Z-sequence (5’-ACTGAACCTGACCGTACA-3’), which is
complementary to the universal Z probe (Intergen Inc., Oxford,
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Table I. Transcript levels of activin receptor-like kinase 7 (ALK7) in
breast cancer. (Samples collected from the BroTaf Health Authority
Wales, UK).
Clinical/pathological         Samples,       ALK7 Copy no.,        p-Value
feature                                        n                     mean±SD
Tissue sample                                                                                       
   Normal                                  20                5,591±12,037                 
   Tumor                                    91              38,370±342,921           0.015
Grade                                                                                                    
   1                                             11                    194±507                      
   2                                             31             107,009±587,440          0.597
   3                                             48                3,578±14,072             0.206
NPI                                                                                                        
   1 (<3.5)                                 44              75,819±493,086               
   2 (3.5-5.4)                             30                5,143±17,619             1.000
   3 (>5.4)                                 13                    69±142.8                 0.518
TNM                                                                                                     
   1                                             47              70,696±477,144               
   2                                             31                2,659±11,001             0.091
   3                                              5                  141.2±173.2              0.545
   4                                              4                    39.8±36.2                0.195
Clinical outcome                                                                                  
   Disease-free                          63                 2,205±9,142                   
   Poor outcome                                                                                    
   With metastasis                      5                15,510±15,497            0.935
   With local recurrence            4                  107.2±169.1              0.570
   Died of breast cancer           14             233,767±874,464          0.746
Histology                                                                                              
   Ductal                                    71                2,499±11,647                  
   Lobular                                  11             297,640±986,484          0.422
   Other                                       5                  136.1±184.0              0.900
ER status                                                                                               
   ERα −                                    57              59,967±433,194               
   ERα +                                    30                2,382±11,095             0.904
   ERβ −                                    69              49,929±393,773               
   ERβ +                                    20                 2,225±8,805              0.673
NPI: Nottingham Prognostic Index; TNM: tumour/lymph
node/metastasis system; ERα/β: oestrogen receptor alpha/beta. Bold p-
values are statistically significant.
UK). The reaction was carried out on an iCycler-IQ™ (Bio-Rad,
Hemel Hemstead, UK). The reactions were carried out at 95˚C for
10 min, 100 cycles of 95˚C for 15 s, 55˚C for 35 s and 72˚C for 
10 s. The primers used for qPCR included: ALK7 F: 5’-
GACATGAAAACATCCTTGGT-3’, ALK7 R: 5’-ACTGAACCT
GACCGTACATTCAGATACCAGCCAAAGTT-3’; GAPDH F: 5’-
CTGAGTACGTCGTGGAGTC-3’, GAPDH R: 5’-ACTGAACC
TGACCGTACACAGAGATGACCCTTTTG-3’.
Construction of ALK7 expression plasmid and the establishment of
corresponding stable transfectants. ALK7 cDNA was generated by
RT-PCR using the primers: 5’-ATGACCCGGGCGCTCTG-3’ and
5’-TTAGGCTTTGCAGTCTTCTTTGACA-3’. Full-length wild-
type ALK7 was then cloned into a pEF6/V5-HisTOPO vector
(Invitrogen, Paisley, Scotland, UK). Plasmids were sequenced and
verified. pEF6-ALK7 and empty plasmids (pEF6-Empty) were
transfected into both MDA-MB-231 and MCF-7 cells using an
Easyjet Plus electroporator (EquiBio, Kent, UK). After 2 weeks of
selection with 5 μg/ml blasticidin, the verified transfectants were
clonally expanded and cultured in maintenance medium containing
2.5 μg/ml blasticidin. ALK7 overexpression was then confirmed by
qPCR and western blot. The resulting cell lines were then named
MCF-7 ALK7 OE1 and -2, and MDA-MB-231 ALK7 OE (OE
overexpression). Control cell lines with integrated pEF6 empty
vector were called MCF-7 or MDA-MB-231 pEF6. 
In vitro cell growth assay. Cells (3x103 cells/well) were plated into
96-well plates and allowed to grow. Cells were fixed in 4% formalin
after 24, 72, 120 and 168 h of culture. The cells were then stained
with 0.5% (w/v) crystal violet solution. Following washing, stained
crystal violet was dissolved with 10% (v/v) acetic acid (20).
Absorbance was then determined at 540 nm using an ELx800
spectrophotometer (BioTek).
In vitro cell-matrix adhesion. Cells (2x104) were added to each well
of a 96-well plate, which was pre-coated with Matrigel (BD
Biosciences, Oxford, UK). After 40 min of incubation, non-adherent
cells were washed off using balanced salt solution buffer. The
remaining cells were fixed with formalin and stained with crystal
violet. The number of adherent cells was then counted under a
microscope. 
In vitro invasion assay. This was performed as previously reported
and modified in our laboratory (21). Briefly, transwell inserts
(Greiner Bio-One Ltd, Stonehouse, UK) with 8 μm pores were
coated with Matrigel and air-dried. The Matrigel was rehydrated for
40 min before use. Then 2x104 cells were seeded into each insert.
After 72-h incubation, cells that had migrated through the matrix
and adhered on the other side of the insert were fixed and stained
with crystal violet. The number of invading cells were then counted
under a microscope.
Western blot analysis. Equal amounts of protein (20 μg) from breast
cancer cell lysates, were separated using sodium dodecyl sulfate
polyacrylamide gel electrophoresis and electroblotted into
nitrocellulose membranes, and then blocked in 5% milk in TBS-
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Figure 1. A high level of activin receptor-like kinase 7 (ALK7) expression in breast tumours correlates with longer overall survival. Kaplan–Meier
model of survival according to ALK7 expression in patients with breast cancer. Data were taken from Affymetrix microarrays only. A and B represent
two different clinical datasets for breast cancer.
Tween20 (0.5%). Proteins were then probed with the respective
primary antibodies (GAPDH and ALK7 antibodies were obtained
from Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and
corresponding peroxidase-conjugated secondary antibodies (Agilent
Technologies Inc, Santa Clara, CA, USA). Protein bands were
visualised using a chemiluminescence detection kit (Luminata;
Millipore, Billerica, MA,, USA) and visualised using a UVITech
imager (UVITech, Cleaver Scientific Ltd, Rugby, UK). Bands were
measured quantitatively using the Image J software.
Drug treatments and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) cell viability assays. For the cytotoxicity
experiments, we used tamoxifen, paclitaxel (Sigma, USA) and
cisplatin (EDQM, France). Cells were seeded at 3x103 per well in
96-well plates for 24 h. Cells were then treated with tamoxifen (0-
100 μM), paclitaxel (0-10 nM) or cisplatin (0-300 μM) for 4 days.
MTT solution (0.5 mg/ml) was then added to each well and incubation
was continued for 4 h at 37˚C. Dimethyl sulfoxide was then added to
dissolve the dye and the absorbance was then recorded at 540 nm. 
Statistical analysis. Statistical analysis was performed using
SPSS18 (SPSS Inc., Chicago, IL, USA). Mann-Whitney U-test was
used for non-normally distributed data, and the t-test was used for
normally distributed data. Survival was analysed using Kaplan–
Meier survival analysis. Values of p<0.05 were considered
statistically significant.
Results
High expression of ALK7 correlates with better survival in
patients with breast cancer. We analyzed the clinical data of
patients with breast cancer from Kmplot.com website - a
manually curated database. Gene-expression data and
relapse-free and overall survival information were
downloaded into a database handled by a PostgreSQL server,
which integrates gene expression and clinical data
simultaneously. The Kaplan–Meier survival model was used
to analyze the overall survival. We found high ALK7
expression was associated with longer overall survival of
patients with breast cancer which can be seen from the two
data sets [n=1660. hazard ratio (HR)=0.69, p<0.0001;
n=1660. HR=0.65, p<0.0001) (Figure 1).
Expression of ALK7 in breast cancer and breast cancer cell
lines. The expression of ALK7 was examined in breast cancer
cell lines and a cohort of breast cancer tissues by qPCR
analysis. From the clinical cohort, we found that the transcript
levels were increased overall breast cancer samples compared
with normal tissue. ALK7 expression decreased with
increasing clinic stage of breast cancer (invasive ductal cancer
patients with TNM stage 2, 3 or 4 expressed lower levels of
ALK7 compared to those with TNM 1 stage, p=0.014). In
addition, patients with a higher Nottingham Prognostic Index
had lower ALK7 expression. However, these data did not reach
significance. Furthermore, the relationship between expression
of ALK7 and ER was also analysed. There was a reduction in
ALK7 expression with ERα and ERβ positivity but again not
reaching statistical significance.
We analyzed ALK7 expression levels in eight human
breast cancer cell lines. We found a high degree of variability
across the cell line panel with BT-20. BT-549, BT483 and
SK-BR-3 cell lines showing high expression, MCF-7 and
MDA-MB-436 showing moderate expression, and MDA-
MB-231, ZR-75-1 showing low expression (Figure 2A). 
As ALK7 expression levels were reduced in high-grade
and high-stage breast cancer, we decided to further our
studies using the MCF-7 and MDA-MB-231 cells as these
two cell lines represent hormone-sensitive (ERα+) and triple-
negative breast cancer cell lines, respectively, two of the
most common breast cancer subtypes. Upon western blot for
ALK7 protein, a reduced level of expression was seen in
MDA-MB-231 compared to MCF-7 cells (Figure 2B and C).
Overexpression of ALK7 in breast cancer cell lines. In order to
study the effects of ALK7 upon these breast cancer cells, we
generated two stable breast cancer cell lines, MDA-MB-231 and
MCF-7, ectopically expressing ALK7 cDNA. The
overexpression of ALK7 was verified in the stable cell lines
using qPCR, and western blot (Figure 3). Increased expression
of ALK7 was seen in both ALK7-overexpressing MDA-MB-231
ALK7 OE ALK7 OE and MCF-7 ALK7 OE cells compared to
their corresponding controls including cells stably transfected
with the empty plasmid and the wild-type parental cells.
ALK7 overexpression reduces growth, adhesion and invasion
of breast cancer cells. The effects on cell functions induced
by ALK7 overexpression were examined by several assays,
including cell growth, adhesion, and invasion. We firstly
determined the effect of ALK7 overexpression on cell
growth in vitro. Overexpression of ALK7 in MCF-7 ALK7
OE cells significantly reduced the growth rate over 7 days
(Figure 4A). MDA-MB-231 ALK7 OE cells showed a
similar trend, but there was no significant difference
compared to parental cell line. 
Overexpression of ALK7 in both MCF-7 and MDA-MB-231
cells had a significant influence on cell matrix adhesion. As
shown in Figure 4B, overexpression of ALK7 in MCF-7 ALK7
OE and MDA-MB-231 ALK7 OE cells significantly reduced
cell adhesion (MCF-7 ALK7 OE1 p=0.0319; MCF-7 ALK7
OE p=0.0318; MDA-MB-231 ALK7 OE p=0.0325) compared
with control wild-type cells.
Matrigel invasion assays were used to evaluate the invasive
capability of breast cancer cells. Overexpression of ALK7 in
MCF-7ΔALK7 and MDA-MB-231ΔALK7 cells reduced their
invasive capability but not significantly (p>0.05) (Figure 4C).
ALK7 is repressed by Oestrogen in MCF-7 cells. We treated
hormonally starved wild-type MCF-7 cells (72 h) with
different concentrations of oestradiol and tamoxifen for 
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24 h. Upon starvation of oestrogen, we saw a significant
increase in ALK7 expression, which was then reduced upon
Oestrogen treatment (0.01-100 nM) (Figure 5A). As a positive
control for Oestrogen activity in these cells, we monitored the
increased expression of the oestrogen-regulated gene
progesterone receptor (PR) (Figure 5B). Tamoxifen treatment
of wild-type MCF-7 cells in full medium (with oestrogen) led
to a modest increase in expression at low doses (Figure 5C) –
thus verifying that ALK7 expression is in some way
suppressed by Oestrogen. PR expression was significantly
supressed by tamoxifen at all concentrations (Figure 5D).
Cytotoxicity of paclitaxel and cisplatin. In order to
investigate the effects of ALK7 on the chemotherapeutic
responsiveness of breast cancer cell lines, we treated MCF-
7, MDA-MB-231, MCF-7 ALK7 OE and MDA-MB-231
ALK7 OE, with different concentrations of paclitaxel and
cisplatin for 96 h, followed by MTT cell viability assays. We
found that overexpression of ALK7 increased the sensitivity
of MCF-7 cells to paclitaxel (Figure 6A), but had a smaller
non-significant effect on MDA-MB-231 sensitivity (Figure
6B). However, ALK7 overexpression slightly increased
resistance to cisplatin in both cell lines (Figure 7). 
Hu et al: ALK7 Expression in Breast Cancer
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Figure 2. Expression of activin receptor-like kinase 7 (ALK7) in breast cancer cell lines. A: Analysis of ALK7 expression in a panel of breast cancer
cells lines. Results represent the means± SD of three independent experiments. Data were normalised to expression of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and β-actin. B: Western blot analysis of ALK7 protein expression in MCF-7 and MDA-MB-231 cell lines. Protein loading
is shown by GAPDH. C: Densitometric analysis of western blot band intensity of ALK7, as normalised to GAPDH level.
Discussion
The TGF-β superfamily includes many structurally and
functionally related growth factors (22). These factors initiate
their cellular effects by binding to cell surface receptors,
including type I and type II serine/threonine receptors. ALK7
is one such type I receptor. The loss or reduction of TGF-β
type II and type I receptor expression is a frequent genetic
event in a variety of human cancer types (23-25). The activin
type I receptor mRNA levels are significantly lower in prostate
tumors when compared to non-malignant tissues (26). An
early study reported immunohistochemical analyses showing
ANTICANCER RESEARCH 37: 3441-3451 (2017)
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Figure 3. Overexpression of activin receptor-like kinase 7 (ALK7) in breast cancer cells. A: Analysis of ALK7 expression in MCF-7 (left hand side)
and MDA-MB-231 (right hand side) ALK7-overexpressing (OE) cells compared to wild type (WT) and pEF6-empty control (pEF6). B: Western blot
analysis of ALK7 levels in MCF-7 (left hand side) and MDA-MB-231 (right hand side) overexpression cells in comparison to wild type and pEF6-
empty controls. Protein loading was verified by the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) blot. C: Densitometric analysis of the
western blot bands to determine the ratio of ALK7 expression in MCF-7 and MDA-MB-231 cells. **p<0.01, ***p<0.001, ****p<0.0001.
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Figure 4. The effects of activin receptor-like kinase 7 (ALK7) overexpression on cell growth, adhesion, and invasion by breast cancer cells. A: Cell
proliferation assays of MCF-7 ALK7-overexpressing (OE) and MDA-MB-231 ALK7 OE cells compared with wild-type (WT) controls over 7 days.
Data were normalised to day 1. B: Cell adhesion assays of MCF-7 ALK7 OE and MDA-MB-231 ALK7 OE cells compared to wild-type controls.
Data represent mean cell counts from three independent experiments. C: Invasion assays of MCF-7 ALK7 OE and MDA-MB-231 ALK7 OE cells
compared with wild-type controls. Data represents mean cell counts from three independent experiments. Cells were stained with crystal violet and
representative images are shown. *p<0.05, **p<0.01.
that ALK7 was more frequently and much more intensely
expressed in adjacent normal tissues, adenosis, and
fibroadenoma tissues than in malignant tissues (ductal
carcinoma in situ, invasive ductal cancer, and lymph node
metastasis). Patients with pancreatic ductal adenocarcinoma
with a lack of ALK7 expression survived for a significantly
shorter time than patients with positive ALK7 expression (17).
Lack of ALK7 expression was confirmed as a factor of poor
prognosis in patients with PDAC by others (27). According to
the Kaplan–Meier survival model from the Kmplot database,
we found that patients with breast cancer with high ALK7
expression had longer overall survival. These findings suggest
that the abnormal expression of TGF-β superfamily receptors
may be important for the progression of cancer.
ANTICANCER RESEARCH 37: 3441-3451 (2017)
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Figure 5. Activin receptor-like kinase 7 (ALK7) expression is Oestrogen regulated in MCF-7 cells. A: Quantitative polymerase chain reaction (Q-
PCR) analysis of ALK7 expression levels in MCF-7 cells grown hormonally starved for 72 h, and then treated with increasing doses of oestrogen
(0-100 nM). B: Q-PCR analysis of progesterone receptor (PR) expression levels in MCF-7 cells grown hormonally starved for 72 h, and then treated
with 10 nM Oestrogen (E2). C: Q-PCR analysis of ALK7 expression levels in MCF-7 cells grown in full medium treated with increasing doses of
tamoxifen (0-20 μM) for 24 h. D: Q-PCR analysis of progesterone receptor (PR) expression levels in MCF-7 cells grown in full medium treated
with increasing doses of tamoxifen (0-20 mM) for 24 h. *p<0.05, **p<0.01, ***p<0.001.
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Figure 7. Cytotoxicity assays of MCF-7 activin receptor-like kinase (ALK7)-overexpressing (OE) and MDA-MB-231 ALK7 OE cells compared to
their parental cell lines. Cell proliferation assays were carried out of MCF-7 (A) and MDA-MB-231 (B) cells treated with increasing concentrations
of cisplatin (μM) for 96 h. The half-maximal inhibitorory concentration (IC50) for cisplatin for each cell line is given below each graph.
Figure 6. Cytotoxicity assays of MCF-7 activin receptor-like kinase 7 (ALK7)-overexpressing (OE) and MDA-MB-231 ALK7 OE cells compared to
their parental cell lines. Cell proliferation assays of MCF-7 (A) and MDA-MB-231 (B) cells treated with increasing concentrations of paclitaxel
(μM) for 96 h. The half-maximal inhibitorory concentration (IC50) for paclitaxel for each cell line is given below each graph.
ALK7 influences cell proliferation and induces cell
apoptosis and these effects have been found in a rat neuronal
cell line, hepatoma cells, human trophoblast cells and ovarian
cancer cells (12, 14-16, 19). We also found a similar
phenomenon in breast cancer cell lines MDA-MB-231 and
MCF-7 and this was consistent with the result from a study on
ZR-75-30 breast cancer cell (17). Activins are ligands of
ALK7. Activin has complex effects on cell growth during
branching morphogenesis, but it is generally considered as an
inhibitor of cell proliferation (28). Activin B inhibits cell
proliferation in many cell types (29, 30). Therefore,
presumably, activin B inhibits the proliferation of breast cancer
cells. Activin B-treated ZR-75-30 breast cancer cells showed
decreased cell proliferation after overexpressing ALK7 (22).
Nodal signals through type II activin receptors, including
ALK7 (9, 31). Activation of ALK7 was shown to inhibit cell
proliferation and to induce morphological differentiation in the
rat neuronal cell line PC12 (11) ALK7 also induced apoptosis
in a variety of cell types, such as hepatoma, trophoblast,
epithelial ovarian cancer cells (12, 15, 16). Nodal has similar
growth-inhibiting, apoptosis-inducing effects to ALK7 on
trophoblast and ovarian cancer cells (14). Previous studies
have shown that nodal, acting through ALK7 and SMAD2/3,
exerts antiproliferative and apoptotic effects on human
trophoblast and ovarian cancer cells (15, 16, 32). In breast
cancer cells, nodal and ALK7 up-regulated the cell-cycle
inhibitors p27 and p21 (18). Nodal and ALK7 have been
reported to inhibit AKT activity, as well as the expression of
X-linked inhibitor of apoptotic protein (XIAP) (22). It has also
has been reported that nodal and ALK7 reduced expression of
B-cell lymphoma 2 (BCL2) and B-cell lymphoma-extra large
(BCL-XL), and caspase-3 was activated significantly.
Therefore, overexpression of ALK7 may reduce cell growth
through the nodal/ALK7 pathway. But involvement of these
pathways in the negative regulation of ALK7 on growth,
adhesion and invasion of breast cancer cell is yet to be
investigated. From the results of treatment with oestrogen we
saw that ALK7 expression was repressed by oestrogen in
MCF-7 cells, and found increased expression when oestrogen
was removed or inhibited by the oestrogen antagonist
tamoxifen. We also saw reduced ALK7 expression in the
clinical cohort in ERα+ and ERβ+ samples (albeit not
significantly). We found that ALK7 overexpression increased
the sensitivity of MCF-7 cells to paclitaxel but slightly
reduced the sensitivity of breast cancer cells to cisplatin. The
mechanism of how ALK7 overexpression influences the
sensitivity of MCF-7 cells to chemotherapies is still unknown.
One hypothesis is via the influence of ALK7 on AKT activity
and XIAP expression (13, 16, 33), which has been reported to
promote chemoresistance in ovarian cancer cells (34-37). 
We found ALK7 expression to be inversely correlated
with survival and disease stage and grade. Overexpression
of ALK7 results in reduced cell growth and invasive/motility
characteristics of breast cancer cells. Interestingly, ALK7
seems to be repressed by Oestrogen in ER+ MCF-7 cells,
which have a modest ALK7 expression compared to ER−
MDA-MB-231 cells which showed high expression. Given
that ALK7 expression can alter sensitivity to commonly used
chemotherapeutic agents paclitaxel and cisplatin, the fact that
oestrogens and ER-modulatory therapies (e.g. tamoxifen)
commonly used in ER+ breast cancer may affect ALK7
expression levels and subsequent response to chemotherapy
should be taken into account.
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